Posts by Noopur S. Raje, MD
CAR T-cell Therapy Shows Promise for Refractory/Relapsed Multiple Myeloma
Noopur Raje, MD, of the Massachusetts General Hospital Cancer Center, and colleagues determined in a phase 1 trial that idecabtagene vicleucel had promising antitumor activity in a heavily pretreated population of patients with multiple myeloma, and most nonhematologic toxic effects were grade 1 or 2.
Dr. Raje is associate professor of medicine at Harvard Medical School and director of the Multiple Myeloma Center at Massachusetts General Hospital. She spearheads a translational research program evaluating novel therapeutics in myeloma with a special interest in the biology of myeloma bone disease. Dr. Raje is a member of the International Myeloma Working Group and NCCN Clinical Practice Guidelines Committee for Multiple Myeloma.